- Home
- » Tags
- » Trastuzumab deruxtecan
Top View
- Phesgo (Pertuzumab/Trastuzumab/Hyaluronidase-Zzxf)
- Oncology Dose Reduction Program Beginning July 1, 2021
- Immunotoxin Screening System: a Rapid and Direct Approach to Obtain Functional Antibodies with Internalization Capacities
- Enhertu® (Fam-Trastuzumab Deruxtecan-Nxki)
- Trastuzumab Deruxtecan-Nxki) for Injection, for Reduction, Or Discontinuation of ENHERTU
- Injectable Anti-Cancer Medications
- Update on Molecular Pathology and Role of Liquid Biopsy in Nonsmall Cell Lung Cancer
- Development of HER2-Targeted Therapies for Gastrointestinal Cancer
- Antibody Drug Conjugates: Future Directions in Clinical and Translational Strategies to 2 Improve the Therapeutic Index
- Bladder Cancer
- Gastric Cancers
- PDF of Antibody News
- The Oncology Market for Antibody–Drug Conjugates
- Strategic Collaboration in Oncology Trastuzumab Deruxtecan (DS-8201)
- Transmittal 10166 Date: June 5, 2020 Change Request 11814
- Targeted Therapy in Advanced and Metastatic Non-Small Cell Lung Cancer
- DAIICHI SANKYO CO., LTD. Sunao Manabe President and CEO June 8, 2021
- Phesgo™ (Pertuzumab, Trastuzumab and Hyaluronidase-Zzxf)
- Therapeutic Advances in Oncology
- Labels to Ensure That the Drug Being Prepared and Administered Is PHESGO and Not Intravenous Pertuzumab, Or Intravenous Trastuzumab, Or Subcutaneous Trastuzumab
- Trastuzumab Deruxtecan
- New Drug Approval
- Therapeutic Potential of Antibody-Drug Conjugate-Based Therapy in Head and Neck Cancer: a Systematic Review
- Table 1. Summary of Kinase Inhibitors Approved by the FDA for Treatment
- SAFE HANDLING of HAZARDOUS DRUGS Updated 5/22/2020
- Adult Antiemetic Management of Chemotherapy-Induced Nausea
- Kadcyla® (Ado-Trastuzumab Emtansine)
- Herceptin Hylecta®) Prior Authorization Drug Coverage Policy
- U3-1402, a Novel HER3-Targeting Antibody-Drug Conjugate, for the Treatment of Colorectal Cancer
- Why Novel Later-Line Treatment Options Are Needed for Advanced HER2
- Breast Cancer in Focus
- Current Specialty Pharmacy Drugs (As of July 1, 2021*) New Drugs Indicated in Red
- Expanding Therapeutic Frontiers in Metastatic HER2-Positive Breast Cancer
- Fam-Trastuzumab Deruxtecan-Nxki (Enhertu®)
- Non-Small-Cell Lung Cancer: New Rare Targets—New Targeted Therapies—State of the Art and Future Directions
- Comparative Analysis of Drug Response and Gene Profiling Of
- HER2 Heterogeneity and Resistance to Anti-HER2 Antibody-Drug Conjugates
- Enhertu, IIN-Trastuzumab Deruxtecan
- Table of Contents (PDF)
- Pertuzumab, Trastuzumab, and Hyaluronidase-Zzxf (Phesgo™)
- Clinical Pharmacology Strategies in Supporting Drug Development and Approval of Antibody–Drug Conjugates in Oncology
- Meridian Consult Managed Procedure Code List 2020
- Antibody News You Should Know July 1 - 15, 2020
- Crizanlizumab-Tmca
- Discovery Research and Translation Science of Trastuzumab Deruxtecan, from Non-Clinical Study to Clinical Trial
- Generic (Brand) Name Mechanism of Action Mechanism of Action
- The Exciting New Field of HER2-Low Breast Cancer Treatment
- Ado-Trastuzumab Emtansine (Kadcyla®)
- Enhertu® (Fam-Trastuzumab Deruxtecan-Nxki)
- Targeted Therapy in Esophageal Cancer
- Herceptin Hylecta™ (Trastuzumab and Hyaluronidase-Oysk)
- Hazardous Medication Precautions: Personal Protective Equipment (Ppe)
- Publication Agenda CHMP 07-10 December 2020
- QUICK FACTS FY 2020 AS of 12/31/2020: Other Solid Tumors
- (DS-8201A) in Subjects with HER2-Low Expressing Breast Cancer
- HER2-Overexpressing/Amplified Breast Cancer As a Testing Ground for Antibody-Drug Conjugate Drug Development in Solid Tumors